Endings and beginnings:

We close out 2 studies this week in CareCT, the NC-009 study sponsored by Global TB Alliance which has introduced a new TB drug sorfequiline ( a second gen bedaquiline without some its side effects) and A Study to Evaluate the Long-Term Safety of Astegolimab in Participants With Chronic Obstructive Pulmonary Disease (COPD)

ClinicalTrials.gov ID NCT05878769

Sponsor Hoffmann-La Roche

At the same we have started the Balance study An open label randomised-controlled trial to evaluate the benefit-risk of 1-month rifapentine and isoniazid compared to standard of care to prevent tuberculosis and reduce morbidity in people with diabetes and the Qiastat/Qiagen respiratory panel validation of covid and other respiratory diseases